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Acute mountain sickness is related to nocturnal hypoxemia but
not to hypoventilation
Abstract
The purpose of the study was to investigate determinants of acute mountain sickness after rapid ascent
to high altitude. A total of 21 climbers were studied ascending from <1,200 m to Capanna Regina
Margherita, a hut in the Alps at 4,559 m, within <24 h. During their overnight stay at 4,559 m, breathing
patterns and ventilation were recorded by calibrated respiratory inductive plethysmography along with
pulse oximetry. In the following morning, acute mountain sickness was assessed. Altogether, 11
mountaineers developed pronounced symptoms of acute mountain sickness (Lake Louise score > or =5)
and 10 did not (controls). Compared to controls, subjects with acute mountain sickness had lower
nocturnal oxygen saturation (mean+/-SD 59+/-13% versus 73+/-6%), higher minute ventilation
(7.94+/-2.35 versus 6.06+/-1.34 L x min(-1)), and greater mean inspiratory flow, a measure of
respiratory centre drive (0.29+/-0.09 versus 0.22+/-0.05 L x s(-1)). Periodic respiration was prevalent
but not significantly different among the two groups (apnoea/hypopnea index 60.1+/-34.6 versus
47.1+/-42.6 events per h). The data suggest that pronounced nocturnal hypoxemia, which was not
related to hypoventilation, may have promoted acute mountain sickness. Periodic breathing seems not to
play a predominant role in the pathogenesis of acute mountain sickness.
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ABSTRACT: The purpose of the study was to investigate determinants of acute
mountain sickness after rapid ascent to high altitude.
A total of 21 climbers were studied ascending fromv1,200 m to Capanna Regina
Margherita, a hut in the Alps at 4,559 m, withinv24 h. During their overnight stay at
4,559 m, breathing patterns and ventilation were recorded by calibrated respiratory
inductive plethysmography along with pulse oximetry. In the following morning, acute
mountain sickness was assessed.
Altogether, 11 mountaineers developed pronounced symptoms of acute mountain
sickness (Lake Louise score o5) and 10 did not (controls). Compared to controls,
subjects with acute mountain sickness had lower nocturnal oxygen saturation (mean¡SD
59¡13% versus 73¡6%), higher minute ventilation (7.94¡2.35 versus 6.06¡
1.34 L?min-1), and greater mean inspiratory flow, a measure of respiratory centre
drive (0.29¡0.09 versus 0.22¡0.05 L?s-1). Periodic respiration was prevalent but not
significantly different among the two groups (apnoea/hypopnea index 60.1¡34.6 versus
47.1¡42.6 events per h).
The data suggest that pronounced nocturnal hypoxemia, which was not related to
hypoventilation, may have promoted acute mountain sickness. Periodic breathing seems
not to play a predominant role in the pathogenesis of acute mountain sickness.
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Otherwise healthy subjects ascending rapidly to altitudes
w2,500 m often develop acute mountain sickness (AMS), a
condition characterised by insomnia, headache, dizziness, loss
of appetite, nausea and vomiting [1]. In the Alps, symptoms
and signs of AMS sufficiently severe to force a reduction in
activity were found in 6–8% of climbers examined at altitudes
between 2,850 and 3,650 m, and in 30% of climbers at
4,559 m [2]. AMS is promoted by a rapid ascent rate, depends
on the altitude reached, and on acclimatisation [3]. It occurs
in both sexes, at all ages, and athletic fitness does not protect
against it [1, 4, 5].
Despite its high prevalence, the pathophysiology of AMS is
incompletely understood. Hypoxia seems to play an impor-
tant role [3, 6, 7]. A reduced ventilatory response to hypoxia,
and impaired pulmonary gas exchange related to pulmonary
fluid accumulation, and water and salt retention have been
implicated in development of exaggerated hypoxemia in
subjects with AMS [8–10]. As AMS often develops or worsens
over the night, when periodic breathing and repetitive oxygen
desaturation are also prevalent, a causal relationship or a
common pathophysiological pathway have been evaluated
[11, 12]. However, the results of these earlier studies were
inconclusive due to the small number of subjects with AMS
enrolled, and the lack of quantitative estimation of ventilation
during sleep.
Therefore, the purpose of the current study was to further
explore the potential role of periodic respiration, and other
characteristics of breathing patterns, in promoting AMS by
employing calibrated respiratory inductive plethysmography
to unobtrusively monitor nocturnal ventilation and breathing
patterns in relation to AMS. To evaluate the hypothesis that
AMS is mainly promoted by hypoxia, the evolution of
breathing patterns and oxygenation over two successive
nights at 3,560 m and 4,559 m, respectively, in mountaineers
ascending from lowlands to 4,559 m within v24 h were
studied. Clinical and physiological observations were com-
pared among mountaineers developing AMS (AMS-group)
and those remaining well (controls).
Methods
Subjects
A total of 25 healthy volunteers were recruited among
mountaineers arriving at the Gnifetti hut (3,610 m), Mt.
Rosa, Italy, to spend a night there. All had ascended in the
afternoon from Alagna (1,170 m) to Punta Indren (3,220 m)
by cable car, and had subsequently walked to 3,610 m within
1–2 h. To be included into the study, subjects had to have no
history of previous high altitude pulmonary oedema, and they
had to have spent no more than 7 daysw2,500 m within the
last 30 days. They gave informed consent to participate in
the study, which was approved by the Ethics Committee of
the University Hospital of Zurich.
Measurements
Clinical evaluation. A medical history and physical
examination were performed. Arterial blood gas samples
were drawn from the radial artery while the subjects rested
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quietly in supine position. The specimen was analysed
immediately (Ciba-Corning Diagnostics, Dietlikon,
Switzerland). The alveolar-arterial oxygen partial pressure
gradient was calculated as:
AaD,O2~PA,O2Pa,O2 ð1Þ
Where Pa,O2 is arterial oxygen tension. Alveolar PO2 (PA,O2)
was derived from the simplified alveolar gas equation as:
PA,O2~0:21|(Pb  47)Pa,CO2|(F I,O2z(1F I,O2)=R) ð2Þ
Where Pa,CO2 is carbon dioxide arterial tension and FI,O2 is
inspiratory oxygen fraction. R was assumed to be 0.85 [13].
AMS was assessed according to the Lake Louise protocol (self-
report and clinical assessment) (see Appendix) [14]. A scoreo5
was considered to indicate AMS [2]. Subjective sleep
disturbance was rated on a three-point Likert scale where
0=satisfactory, and refreshing sleep, 1=moderate sleep
disturbance, and 2=severe sleep disturbances with difficulties
falling asleep, multiple awakenings, and unrefreshing sleep.
Cardiorespiratory sleep studies. Nocturnal breathing patterns
were recorded as previously described [15] by computerised
devices incorporating a respiratory inductive plethysmograph,
a pulse oximeter, an ECG, and a position sensor (Somnostar,
SensorMedics, Yorba Linda, CA, USA, or LifeShirt,
VivoMetrics, Ventura, CA, USA). Displacement of
inductance sensors was avoided as they were built into a
snugly fitting shirt (LifeShirt), or were taped to the skin and
secured with an elastic net (Somnostar). The Qualitative
Diagnostic Calibration method was applied during natural
breathing in supine position over 5 min. It provided relative
gains of rib cage and abdominal inductive plethysmograph
signals [15, 16]. Their sum was subsequently calibrated in
absolute units (L) by rebreathing into a bag of known volume
(0.8 L) for 5–10 breaths with the nose clipped. Accuracy of
calibration was verified in the morning after sleep studies, and
regarded as acceptable if inductive plethysmographic tidal
volumes were within 20% of the calibration bag volume.
Actigraphy. Rest/activity patterns were recorded by an
accelerometer placed at the wrist as an indirect measure of
sleep/wakefulness (Actiwatch; Cambridge Neurotechnology,
Cambridge, UK) [17–19].
Protocol
After the overnight stay at the Gnifetti hut (3,610 m),
subjects hiked to Capanna Regina Margherita (4,559 m) in
the following morning, and spent the second night there. They
redescended on the third day. Clinical assessment of high
altitude illness was performed four times: in the evenings and
mornings at 3,610 and 4,559 m. Cardiorespiratory sleep
recordings and actimetry were obtained twice: during the
nights at 3,610 m and 4,559 m. Arterial blood gas analysis
was performed in the evening and morning at 4,559 m. No
drugs other than paracetamol, and metoclopramide were
allowed.
Data analysis and statistics
Polygraphic recordings were analysed from lights-off in the
evening, at around 22:00 h, to lights-on in the morning, at
around 05:00 h. This period was termed time in bed (TIB).
Inductive plethysmographic tracings were analysed breath by
breath and derived variables averaged over the night [15, 20].
The phase shift between rib cage and abdominal excursions
was calculated [21]. Apnoeas/hypopnoeas were defined as a
reduction of the inductive plethysmographic sum volume
signal tov50% over o10 s in comparison to the preceding
2 min baseline [22, 23]. Transient reductions in breathing
amplitude tov50% baseline over 5–10 s were also scored as
apnoeas/hypopnoeas if they occurred as part of a periodic
breathing pattern with waxing and waning of ventilation with
periods of hyperventilation alternating with central apnoeas/
hypopnoeas over at least three successive cycles (fig. 1) [24,
25]. Central apnoeas/hypopnoeas were identified by absence
of rib cage-abdominal asynchrony [14]. The apnoea/hypopnoea
index was defined as the number of apnoeas and hypopnoeas
per hour TIB. The duration of apnoea/hypopnoea and the
fraction of TIB spent in apnoea/hypopnoea were measured.
The cycle times of periodic breathing, i.e. the duration of a
hyperpnoea and the corresponding apnoea/hypopnoea were
measured. The fraction of TIB spent with periodic breathing
was determined as the sum of all cycle times of periodic
breathing divided by TIB. Counts of oxygen saturation dips
o4% and histograms of oxygen saturation averaged over 1 s
periods were obtained [26]. Rest and activity periods were
derived from actigrams with the aid of dedicated software [17,
18]. The acceleration level below which sleep presumably
prevailed was graphically determined. The time from lights-
off to the first 10 min with immobile data was defined as
estimated sleep latency. The time spent with acceleration
below threshold was termed rest time, and estimated sleep
efficiency was rest time in per cent of TIB.
Normality of distribution was verified by the Kolmogorov-
Smirnov statistics. Results are expressed as mean¡SD.
Subjects were grouped according to whether AMS had
developed, i.e. Lake Louise score was o5, in the morning
after the night at 4,559 m. Measurements at different altitudes
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Fig. 1. – Nocturnal polygraphic recording obtained from a mountain-
eer at 4,559 m. The inductive plethysmographic volume signals of a)
the sum volume (Sum vol.) of the ribcage (RC) and abdomen (AB),
b) the RC volume, and c) the AB volume, illustrate periodic breathing
associated with fluctuations in d) arterial oxygen saturation (Sp,O2) and
e) heart rate (HR). The repetitive apnoeas are scored as central, since
there is no asynchrony among rib cage and abdomen excursions.
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and between groups were compared by analysis of variance
followed by Newman-Keuls tests, where appropriate [27]. The
effect of potential determinants of AMS was evaluated by
logistic regression. A probability of pv0.05 was assumed as
significant. A power of 80% was assumed to represent
appropriate certainty to derive negative conclusions from
nonsignificant inter-group differences.
Results
All 25 subjects completed the protocol. In four subjects, the
cardiorespiratory sleep studies could not be analysed because
of technical failure (three subjects with and one without
AMS). These data had to be discarded. Thus, data of the
remaining 21 subjects (3 females, 18 males, mean¡SD aged
35¡12 yrs) are reported.
Clinical and self-assessment
Clinical examination did not show symptoms or signs of
high altitude pulmonary oedema, nor ataxia or impaired
consciousness (high altitude cerebral oedema) in any subject.
Thus, none of the subjects required treatment for severe high
altitude related illness, and none of them took metoclopra-
mide. In the morning after having spent one night at 4,559 m,
11 of 21 subjects fulfilled the criteria for AMS (Lake Louise
score o5 [2], range 5–10). This group, termed AMS-group,
did not differ in regard to age, sex, or body mass index from
the rest of the subjects, termed controls (table 1). The
tendency of the AMS-group to be sicker than the control
group was already present at lower altitude (evening and
morning at 3,610 m), but this difference became significant
after subjects had spent a night at 4,559 m only. In controls,
the mean change in Lake Louise score from 3,610 m to
4,559 m was not statistically significant (table 1). The AMS-
group experienced major subjective sleep disturbances at
4,559 m, whereas sleep disturbance in controls was only mild
at 3,610 m and 4,559 m.
Arterial blood gas analysis at 4,559 m in the evening and
the following morning revealed a similar degree of hypo-
xemia, and respiratory alkalosis in the AMS-group as in
controls (table 2). The values in the evening were not different
from that in the morning in both groups. The study was
powered with 80% to detect a difference in the Pa,O2 of
1.60 kPa (12 mmHg), in the Pa,CO2 of 0.67 kPa (5 mmHg)
and in the alveolar-arterial oxygen partial pressure gradient of
9 mmHg. Thus, nonsignificant differences in arterial blood
gases might have been related to inadequate sample size.
Overnight recordings
Ascending from 3,560 m to 4,559 m was associated with an
increase in ventilation, mainly related to an increase in tidal
volume, whereas breath rate changed little (table 3). The
increase in ventilation was more pronounced in the AMS
group than in the controls, and only significant in the former.
Accordingly, the AMS group showed a significant increase in
mean inspiratory flow, a measure of respiratory centre drive
[28], in the night at 4,559 m in comparison to the value at
3,560 m and to the corresponding value in controls at
4,559 m. The rib cage versus abdominal phase shift was
similarly low in AMS subjects as in controls at both altitudes
indicating a nearly perfect synchronisation of chest wall
excursions.
Nearly all observed apnoea/hypopnoea were central,
whereas obstructive events with asynchronous rib cage-
abdominal motion were extremely rare, i.e. the obstructive
apnoea/hypopnoea index wasv5 per night in all subjects in
both nights. Therefore, the data on apnoea/hypopnoea are
not split into central and obstructive events. Already at
3,560 m, and even more so at 4,559 m, frequent central
apnoea/hypopnoea occurred, and a significant time of the
night was spent with periodic respiration by the AMS-group
and controls (table 3). Although the AMS-group tended to
have a greater number of events, and a greater fraction of TIB
spent in apnoea/hypopnoea and with periodic respiration, the
differences to the controls were not statistically significant.
Power calculations indicated that the current study was
powered with 80% to detect a difference in the apnoea/
hypopnoea index of 45?h-1, a difference of 47% in time spent
with periodic respiration, and a difference of 18% in time
spent in apnoea/hypopnoea. Therefore, the lack of signifi-
cance (pw0.05) for the observed differences in these outcomes
may have been due to inadequate sample size.
Mean arterial oxygen saturation was lower in the AMS
group than in controls at 4,559 m. Since accuracy of pulse
oximetry is not well established at low values the relative time
spent with oxygen saturation above and below 70% was also
computed. A greater percentage of time was spent at low
oxygen saturation (v70%) by AMS-subjects than by controls
at 4,559 m confirming the impaired oxygenation in the former
Table 1. – Clinical evaluation
Controls AMS group
Subjects n (females) 10 (1) 11 (2)
Age yrs 32¡12 39¡12
Height m 1.77¡0.08 1.77¡0.08
Body mass index kg?m-2 23.5¡2.1 23.4¡2.8
Days spent atw2500 m
in the last 30 days 3.9¡2.6 3.2¡1.8
in the last 7 days 2.4¡2.3 1.8¡1.3
Lake Lousie score
3610 m day 1 Evening 1.5¡1.2 3.5¡1.8
3610 m day 2 Morning 1.9¡1.7 4.2¡1.5
4559 m day 2 Evening 2.8¡1.9 5.5¡2.2#
4559 m day 3 Morning 3.0¡1.2 7.3¡1.6},#,z
Subjective sleep disturbance§
3610 m, day 2 Morning 0.9¡0.7 1.0¡0.6
4559 m, day 3 Evening 0.9¡0.6 1.8¡0.4#,z
Data are presented as mean¡SD. Day 1, 2, 3 refers to the days at
o3610 m; morning and evening. Assessments were performed between
05:00–07:00 h, and 20:00–22:00 h, respectively. #: pv0.05 versus
corresponding value at 3,610 m; }: pv0.01 versus previous evening; z:
pv0.01 versus controls; §: three point Likert scale from 0: satisfactory,
refreshing sleep, to 2: severe sleep disturbance.
Table 2. – Arterial blood gas analysis at 4,559 m
Controls AMS group
Evening Morning Evening Morning
pH 7.56¡0.07 7.54¡0.04 7.58¡0.06 7.55¡0.06
Pa,CO2 mmHg 26¡5 25¡5 24¡3 24¡2
Pa,O2 mmHg 48¡10 52¡13 47¡7 46¡7
Sa,O2 % 87¡7 88¡9 88¡7 86¡8
AaD,O2 mmHg 10¡5 9¡8 12¡5 12¡7
Data are presented as mean¡SD. No significant difference for
comparison of corresponding values among controls and AMS group,
and among evening and morning values. Pa,CO2: carbon dioxide
arterial tension; Pa,O2: arterial oxygen tension; Sa,O2: arterial oxygen
saturation; AaD,O2: alveolar-arterial oxygen partial pressure gradient.
kPa=mmHg60.133. n=10 (controls), 11(AMS group).
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(table 3). The number of oxygen saturation dips o4% in the
AMS group exceeded corresponding values in controls but
these differences were statistically nonsignificant. Heart rate
increased in both groups to a similar extent after ascending to
4,559 m.
In the night at 4,559 m actigraphic recordings revealed that
the AMS-group spent a greater percentage of the night
moving, i.e. had reduced estimated sleep efficiency, than
controls (table 3).
To evaluate potential effects of nocturnal hypoxemia, the
prevalence of apnoea/hypopnoea, and ventilation on the
development of AMS, binary logistic regression analysis was
performed on data from overnight recordings at 4,559 m. The
percentage of time spent at oxygen saturation v70%, the
apnoea/hypopnoea index, and mean nocturnal ventilation
adjusted for body surface area (by dividing ventilation by the
squared height in m [8]) were the independent variables, and
AMS (Lake Louise score o5 or v5 in the morning at
4,559 m) the binary dependent variable. The analysis revealed
that only nocturnal hypoxemia was a significant predictor of
the development of AMS (odds ratio for per cent time spent
with oxygen saturationv70% 1.034, 95% confidence interval
1.001–1.068, p=0.04). Inclusion of overnight changes in Lake
Louise scores into the prediction model did not alter these
results, i.e. nocturnal hypoxemia (per cent time with arterial
oxygen saturation measured by pulse oximetry (Sp,O2)v70%)
remained the only significant predictor for AMS.
Discussion
The current study assessed nocturnal breathing patterns
and oxygenation in mountaineers climbing from lowlands to
4,559 m withinv24 h, in relation to symptoms and signs of
AMS. It was found that the development of AMS after a
night at 4,559 m was preceded by pronounced hypoxemia, a
high, and unstable nocturnal ventilation, and restless sleep.
The data are consistent with the hypothesis that nocturnal
hypoxemia unrelated to hypoventilation but likely due to
impaired pulmonary gas exchange is the major determinant of
AMS, whereas nocturnal periodic breathing seems not to play
a predominant role in promoting AMS.
One of the strengths of the current investigation is the use
of noninvasive techniques for continuous monitoring of
nocturnal breathing patterns. Thus, the well-known effects
of airway instrumentation on ventilation could be avoided
[29]. Furthermore, by calibrating the respiratory inductive
plethysmograph quantitative estimates of ventilation were
obtained in a fairly large number of subjects, information that
has not been available from previous studies in a similar
setting. By requiring inductance plethysmographic derived
tidal volumes to fall within 20% of the reference, i.e. the fixed
volume bag, at the end of overnight recordings, an acceptable
accuracy of the estimates of ventilation was assured.
The more pronounced nocturnal hypoxemia found in
subjects developing AMS in comparison with controls
matched in regard to anthropometric characteristics and
prior acclimatisation is consistent with earlier studies indicat-
ing a central role of hypoxemia in causing AMS [6, 7, 11]. In
contrast, median nocturnal oxygen saturation by pulse
oximetry did not differ among five subjects with AMS and
eight controls (i.e. it was 63% in both) who underwent a
similar ascent protocol to Capanna Regina Margherita, as
that in the current study [12]. This discrepancy may relate to
the fact that EICHENBERGER et al. [12] had assessed AMS by a
clinical score different from the Lake Louise protocol that
was employed in the current study, and to differences in the
prevalence of subclinical pulmonary oedema between the cited
and the current study. Since calibration of pulse oximetry is
less well established at low oxygen saturation (v70%), a
technical dissimilarity in pulse oximeters between studies is an
additional potential explanation for the discrepancy [30].
In the AMS-group, a trend for decreased mean nocturnal
oxygen saturation, augmented ventilation, and symptoms of
Table 3. – Overnight recordings
Controls AMS group
3610 m 4559 m 3610 m 4559 m
Recording time min 438¡62 447¡63 422¡92 454¡42
Ventilation
L?min-1 4.84¡1.19 6.06¡1.34 5.42¡1.67 7.94¡2.35z,§
L?min-1?m2 1.57¡0.45 1.74¡0.56 1.96¡0.50 2.54¡0.80z
Tidal volume L 0.28¡0.07 0.36¡0.10z 0.28¡0.08 0.42¡0.11z
Breath rate Breaths?min-1 17.2¡1.7 17.6¡2.5 19.0¡1.6 19.1¡2.3
Duty cycle tI/tT 0.41¡0.03 0.43¡0.03 0.43¡0.02 0.43¡0.03
Mean inspiratory flow VT/tI L?s-1 0.19¡0.05 0.22¡0.05 0.19¡0.06 0.29¡0.09z,§
Rib cage-abdominal phase shift degrees 11¡3 14¡4 14¡3 16¡5
Apnoea/hypopnoea index events?h-1 28.6¡28.5 47.1¡42.6 20.2¡27.3 60.1¡34.6z
Apnoea/hypopnoea mean durations 13.3¡1.0 10.3¡2.6z 13.5¡1.2 10.3¡3.1z
Time in apnoea/hypopnoea % of TIB 12¡11 16¡17 10¡12 19¡14
Cycle time of periodic breathing s 30¡6 26¡4 29¡4 25¡4
Time with periodic breathing % of TIB 25¡25 34¡33 18¡26 43¡27z
Mean nocturnal Sp,O2 %
# 84¡2 73¡6z 78¡7 59¡13z,§
Time with Sp,O2v70% % of TIB# 0¡0 30¡36 11¡19 74¡39z,§
Sp,O2 dip rate dipsw4%?h-1# 3.7¡2.9 70.8¡38.6z 5.6¡5.9 86.6¡46.2z
Heart rate L?min-1 67¡10 73¡12z 74¡7 81¡12z
Rest time min} 368¡71 378¡54 340¡47 302¡73
Estimated sleep latency min} 17¡9 15¡11 14¡8 25¡46
Estimated sleep efficiency % of TIB} 86¡6 85¡6 80¡8 68¡17z,§
Data are presented as mean¡SD. tI: inspiratory time; tT: respiratory cycle time; VT: tidal volume; TIB: time in bed from lights-off to lights-on; Sp,O2:
arterial oxygen saturation measured by pulse oximetery. #: Sp,O2: oxygen saturation by pulse oximetry available at 3,650 m in nine controls, and five
AMS subjects, at 4,559 m in all 21 subjects; }: actimetry data available at 3,610 m in nine controls, and 10 AMS-subjects, at 4,559 m in 10 controls
and 10 AMS subjects;z: pv0.05 versus 3,650 m; §: pv0.05 versus controls. n=10 (controls); 11 (AMS group).
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AMS already evolved in the first night at 3,650 m. These
differences to the controls became statistically significant over
the course of the night at 4,559 m (table 3). Since mean
nocturnal ventilation in the AMS-group exceeded that of
controls byw30% (table 3), and since mean inspiratory flow
(VT/tI), a measure of central respiratory drive [28], was also
increased by a similar amount in the AMS-group, the data
from the current study do not suggest a reduced central
respiratory drive as the cause of more pronounced hypoxemia
in AMS-subjects. Instead, an impaired pulmonary gas
exchange, possibly related to interstitial fluid accumulation,
seems to be a more likely explanation. Although arterial
blood gas analysis in the morning at 4,559 m revealed a lower
Pa,O2, a lower Pa,CO2, and a greater alveolar-Pa,O2 arterial
oxygen tension gradient (AaD,O2) in the AMS-group than in
controls (table 2), these differences were not statistically
significant. Therefore, the results from the current study do
not substantiate (nor exclude) an impaired gas exchange due
to subclinical pulmonary oedema in the AMS-group.
Potential explanations for this negative finding are an
inadequate sample size or inaccuracies in estimation of the
AaD,O2, which was based on an assumed respiratory exchange
ratio of 0.85. Since the Pa,CO2 values measured in the current
study (table 3) are lower than values observed previously
under similar circumstances [31, 32] it is conceiveable
that the subjects were hyperventilating to some degree,
which might have increased their respiratory exchange ratio.
Nevertheless, an association of a widened AaD,O2 with
AMS has been observed in several previous investigations
[8, 31, 33].
In a study by BARTSCH et al. [8], subjects with AMS
revealed a transient decrease in isocapnic hypoxic ventilatory
response (but neither in poikilocapnic hypoxic nor hypercap-
nic ventilatory response) within 4 h after arrival at 4,559 m,
whereas this was not observed in controls. No differences in
isocapnic and poikilocapnic hypoxic, and in hypercapnic
ventilatory responses were present among AMS and control
subjects at low altitude, and after they had spent a night at
4,559 m. A low ventilatory response to hypoxia has also been
observed in subjects experiencing symptoms of AMS during
short-term exposure to 4,800 m in a hypobaric chamber over
up to 7 h [10]. Thus, subjects prone to AMS may have an
initial relative hypoventilation within hours after rapid ascent
to high altitude. Nevertheless, the lack of differences between
subjects with AMS and controls in measures of ventilatory
response and resting ventilation afterw12 h at 4559 m does
not support a persistent role of impaired ventilatory response
in propagating AMS during prolonged altitude sojourn [8].
Consistent with this hypothesis are the higher nocturnal
ventilation and mean inspiratory flow recorded in the current
study in subjects developing AMS as compared with controls
during a nocturnal recording that startedw10 h after arrival
at 4,559 m (table 3). However, direct measurements of
respiratory drive would have been required to corroborate
this point. A potentially confounding influence on nocturnal
ventilation derives from the sleep/wakefulness-state depen-
dence of ventilatory drive [24]. Since actigraphic recordings
indicate reduced sleep efficiency in AMS subjects, their higher
ventilation might in part be related to a shorter nocturnal
sleep period (table 3). Other unpleasant symptoms of AMS
might also have stimulated ventilation.
Although the apnoea/hypopnoea index, the time spent with
periodic breathing, and oxygen saturation dip rate were
higher during the night at 4,559 m in the AMS-group than in
controls, the differences were not statistically significant
(table 3). Furthermore, only nocturnal hypoxemia, i.e. the
percentage of time spent with low arterial oxygen satura-
tionv70%, was a significant predictor of AMS in a multiple
logistic regression analysis. The odds ratio of 1.034 indicates
that for each % TIB spent with Sp,O2v70%, the risk of
developing AMS is increased by a factor of 1.034. Thus, a
subject spending 74% of time with Sp,O2v70% (i.e. the mean
value of the AMS-group, table 3) has a nearly 12-fold
increased risk (i.e. odds-ratio of 1.03474) of developing
AMS compared with another subject spending the entire
night with Sp,O2w70%. In contrast, mean nocturnal ventila-
tion, and the apnoea/hypopnoea index did not significantly
contribute to the prediction model. Therefore, periodic
breathing seems not to be a critical determinant of AMS,
and in this regard the results from the current study are
consistent with earlier investigations that failed to demon-
strate a significant association of periodic breathing with
development of AMS [11, 12]. Nevertheless, neither the
current nor the earlier studies had sufficient statistical power
to definitively rule out some association of periodic breathing
with AMS.
A limitation of the current and of previous studies on AMS
relates to the lack of objective measures to assess this
condition. This may have hampered a more precise evaluation
of the pathophysiological determinants of AMS.
Conclusions
In unacclimatised mountaineers spending a night in a
mountain hut at 4,559 m, an association among the develop-
ment of acute mountain sickness and preceding pronounced
nocturnal hypoxemia has been confirmed by the current
study. This investigation extends previous studies [11, 12] by
providing quantitative data on nocturnal ventilation and
breathing patterns measured by nonobtrusive means. These
observations are consistent with the hypothesis that the
hypoxemia in subjects with subsequent acute mountain
sickness is not related to nocturnal hypoventilation or
reduced respiratory centre drive, nor to periodic breathing,
although confirmation in a larger number of subjects is
required.
Appendix 1: Assessment of acute mountain sickness
Lake Louise score questions and rating [2, 14]
Self-report by mountaineer:
1. Headache 0 None
1 Mild
2 Moderate
3 Severe, incapacitating
2. Gastrointestinal symptoms 0 None
1 Poor appetite or nausea
2 Moderate nausea
or vomiting
3 Severe nausea or
vomiting, incapacitating
3. Fatigue and/or weakness 0 None
1 Mild
2 Moderate
3 Severe, incapacitating
4. Dizziness/lightheadedness None
Mild
Moderate
Severe, incapacitating
5. Difficulty sleeping 0 Slept as usual
1 Did not sleep
as well as usual
2 Woke up many times,
poor night sleep
3 Could not sleep at all
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The sum of the scores of self-rating and clinical assessment
is the Lake Louise Score. A sum score of o5 was considered
as indicating acute mountain sickness (AMS).
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Clinical assessment by investigator:
6. Change in mental status 0 None
1 Lethargy/lassitude
2 Disoriented/confused
3 Stupor/semiconsciousness
4 Coma
7. Ataxia (heel-to-toe walking) 0 None
1 Manoeuvres to
maintain balance
2 Steps off line
3 Falls down
4 Can9t stand
8. Peripheral oedema 0 None
1 Peripheral oedema
at one location
2 Peripheral oedema at
two or more locations
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